Skip to main content
SpringerLink
Log in

Diabetic nephropathy

Renoprotective effects of pentoxifylline in the PREDIAN trial

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin–angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Navarro-González, J. et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN Trial. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014010012.

  2. Gregg, E. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).

    Article  CAS  Google Scholar 

  3. Vejakama, P. et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55, 566–578 (2012).

    Article  CAS  Google Scholar 

  4. Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C. & Egido, J. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat. Rev. Neph. 10, 325–346 (2014).

    Article  CAS  Google Scholar 

  5. Abdel-Salam, O. M., Baiuomy, A. R., El-Shenawy, S. M. & Arbid, M. S. The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol. Res. 47, 331–340 (2003).

    Article  CAS  Google Scholar 

  6. Shan, D. et al. Pentoxifylline for diabetic kidney disease. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD006800. http://dx.doi.org/10.1002/14651858.CD006800.pub2.

  7. Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540–1546 (2007).

    Article  CAS  Google Scholar 

  8. Perkovic, V. et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517–523 (2013).

    Article  CAS  Google Scholar 

  9. Cowie, C. C. et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N. Engl. J. Med. 321, 1074–1079 (1989).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetic Complications Group, Baker IDI Heart and Diabetes Institute, 75 Commercial Road, 3004, Melbourne, Australia

    Tony He & Mark E. Cooper

Authors
  1. Tony He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Cooper.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, T., Cooper, M. Renoprotective effects of pentoxifylline in the PREDIAN trial. Nat Rev Nephrol 10, 547–548 (2014). https://doi.org/10.1038/nrneph.2014.162

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.162

  • Springer Nature Limited

This article is cited by

Search

Navigation